Antitumor efficacy to PDGFR-targeting drugs seems to depend on similar compensatory signaling mechanisms, as the co-expression of ERBB3, IGF1R and TGFBR2 in PDGFR expressing glioblastoma cells contributes to PDGFR inhibitor resistance [124]. Here, PDGFRB is linked to glioblastoma.